PP
VIRX

Paloma Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Paloma Partners’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-440
Closed -$278K – 1986
2015
Q2 		$278K Buy
+440
New +$234K 0.01% 1369

Other funds holding VIRX

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Paloma Partners's VIRX Position: Q3 2015 in Review

Paloma Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 440 shares — an estimated $278K sold.

Paloma Partners first reported a position in VIRX in Q2 2015 and held it in 1 quarter. The position peaked at $278K in Q2 2015. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

  • Paloma Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Paloma Partners sold 440 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $278K.
  • Paloma Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Paloma Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $278K in Q2 2015.
  • 59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Paloma Partners's 13F filing for Q3 2015, filed 16 Nov 2015.